Cotreatment with ABBV-075 and venetoclax also markedly reduced MYC and CDK6 levels, undermining their likely progrowth and prosurvival effects in the AML cells (Fig. 4b, c). This evidence concerns the gene CDK6 and acute myeloid leukemia.